Reviewing Vivos Therapeutics (NASDAQ:VVOS) & Curaleaf (OTCMKTS:CURLF)

Vivos Therapeutics (NASDAQ:VVOS) and Curaleaf (OTCMKTS:CURLF) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Curaleaf shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Vivos Therapeutics and Curaleaf”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.13	-$21.17 million	($1.90)	-0.08
Curaleaf	$1.27 billion	1.84	-$231.07 million	($0.13)	-76.92

Vivos Therapeutics has higher earnings, but lower revenue than Curaleaf. Curaleaf is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Vivos Therapeutics has a beta of 6.04, meaning that its share price is 504% more volatile than the S&P 500. Comparatively, Curaleaf has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Vivos Therapeutics and Curaleaf, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
Curaleaf	0	0	2	3	3.60

Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 1,638.05%. Given Vivos Therapeutics’ higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Curaleaf.

Profitability

This table compares Vivos Therapeutics and Curaleaf’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-122.00%	-2,325.64%	-102.01%
Curaleaf	-2.62%	-0.88%	-0.26%

Summary

Curaleaf beats Vivos Therapeutics on 8 of the 14 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About Curaleaf

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.